This carefully curated collection features companies providing the essential infrastructure that makes advanced cell and gene therapies possible. Selected by expert analysts, these stocks represent the "picks and shovels" of the biotech revolution—giving you exposure to regenerative medicine's growth without the direct risks of clinical trials.
See the full stock group
Download Nemo to see all stocks in this group
We're focused on the companies behind the scenes making cell and gene therapy possible. Instead of betting on which treatments will succeed, we've selected the firms providing crucial infrastructure—from cryogenic storage to manufacturing components—that all therapies need regardless of clinical outcomes.
These stocks offer a different risk profile than traditional biotech investments. While they still operate in a fast-evolving sector, their services remain essential regardless of which specific therapies ultimately succeed, providing a more stable approach to capturing growth in advanced medicine.
Each company was selected because they provide irreplaceable services in the cell and gene therapy supply chain. As more advanced treatments receive regulatory approval, these firms face increasing demand for their specialized logistics, manufacturing capabilities, and quality control systems.
Cell and gene therapies need ultra-cold storage and transport to work. As more of these treatments get approved, the companies keeping them frozen become critical—an opportunity most investors are missing.
While headline-grabbing biotech firms often face binary outcomes based on clinical trials, these behind-the-scenes companies earn revenue regardless of which therapies ultimately succeed—potentially offering smoother growth.
With cell and gene therapy approvals accelerating, demand for specialized manufacturing and logistics is surging. These companies are positioned to benefit from this momentum as the field transforms from experimental to mainstream.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
Sign up free to view all stocks in this group and never miss out on another investment opportunity with Nemo.
+5
Here are a few of the assets in this group. Create an account to unlock the full list.
Use the growth calculator to see how much investing in these assets could return over one year.
If you invested across these assets:
in 12 months it could be worth:
+891.11%
On average, analysts expect assets in this group to grow 891.11% over the next year.
13 of 15 assets in this group are rated Buy by professional analysts.
This group averaged a 4.9% return last month, beating the typical 4% bank rate.
Ginkgo Bioworks Holdings Inc
DNA
Operates a cell programming platform that provides end-to-end research and development services, acting as a foundational partner in creating and opti...
Operates a cell programming platform that provides end-to-end research and development services, acting as a foundational partner in creating and optimizing cell-based products.
CYTEK BIOSCIENCES INC
CTKB
Develops and manufactures advanced cell analysis systems, which are crucial for research and quality control throughout the cell therapy manufacturing...
Develops and manufactures advanced cell analysis systems, which are crucial for research and quality control throughout the cell therapy manufacturing process.
